



ELSEVIER

Contents lists available at ScienceDirect

## Neuroscience Letters

journal homepage: [www.elsevier.com/locate/neulet](http://www.elsevier.com/locate/neulet)

## Research article

## A pilot study of cell-mediated gene therapy for spinal cord injury in mini pigs



Rustem Robertovich Islamov<sup>a,\*\*</sup>, Mikhail Evgenyevich Sokolov<sup>a,b</sup>,  
Farid Vagizovich Bashirov<sup>a</sup>, Filip Olegovich Fadeev<sup>a,b</sup>, Maxim Michaylovich Shmarov<sup>d</sup>,  
Boris Savelyevich Naroditskiy<sup>d</sup>, Tatyana Vyacheslavovna Povysheva<sup>a</sup>,  
Gulnara Ferdinantovna Shaymardanova<sup>a</sup>, Radik Albertovich Yakupov<sup>c</sup>,  
Yuri Aleksandrovich Chelyshev<sup>a,b</sup>, Igor Aleksandrovich Lavrov<sup>b,e,\*</sup>

<sup>a</sup> Kazan State Medical University, Kazan, Russia<sup>b</sup> Kazan Federal University, Kazan, Russia<sup>c</sup> Kazan State Medical Academy, Kazan, Russia<sup>d</sup> Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia<sup>e</sup> Departments of Neurologic Surgery and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States

## H I G H L I G H T S

- Intrathecal injection of the gene-cell construction was used for the first time for SCI treatment in large animal mini-pig SCI model.
- Results provide evidence of feasibility and potential efficacy of proposed UCBC-based delivery of three therapeutic genes therapy.
- Observed recovery in treated animals support the positive effect of the gene-cell construction after SCI.

## A R T I C L E I N F O

## Article history:

Received 22 June 2016

Received in revised form

24 November 2016

Accepted 12 February 2017

Available online 14 February 2017

## Keywords:

Cell-mediated gene therapy

Adenoviral vector

Spinal cord injury

Mini pigs

Human umbilical cord blood mononuclear cell

Vascular endothelial growth factor (VEGF)

Glial cell-derived neurotrophic factor (GDNF)

Neural cell adhesion molecule (NCAM)

## A B S T R A C T

Currently, in clinical practice there is no efficient way to overcome the sequences of neurodegeneration after spinal cord traumatic injury. Using a new experimental model of spinal cord contusion injury on miniature pigs, we proposed to deliver therapeutic genes encoding vascular endothelial growth factor (VEGF), glial cell line-derived neurotrophic factor (GDNF) and neural cell adhesion molecule (NCAM) to the damaged area, using umbilical cord blood mononuclear cells (UCBC). In this study, genetically engineered UCBC ( $2 \times 10^6$  cells in 200 ml of saline) were injected intrathecally to mini-pigs 10 days after SCI. Control and experimental mini pigs were observed for 60 days after surgery. Histological, electrophysiological, and clinical evaluation demonstrated significant improvement in animal treated with genetically engineered UCBCs. Difference in recovery of the somatosensory evoked potentials and in histological findings in control and treated animals support the positive effect of the gene-cell construction for recovery after spinal cord injury. Results of this study suggest that transplantation of UCBCs simultaneously transduced with three recombinant adenoviruses Ad5-VEGF, Ad5-GDNF and Ad5-NCAM represent a novel potentially successful approach for treatment of spinal cord injury.

© 2017 Elsevier B.V. All rights reserved.

## 1. Introduction

Spinal cord injury (SCI) is classified as a neurotrauma, although it is followed by disturbance in blood supply, neurodegenerative and other pathological consequences [1]. Regardless numerous animal studies and clinical trials, to this time there is no successful clinical protocol for SCI treatment. To enhance the efficacy of SCI therapy along with experiments on rodents and clinical trials, experiments

\* Corresponding author at: Department of Neurologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States.

\*\* Corresponding author.

E-mail address: [lavrov.igor@mayo.edu](mailto:lavrov.igor@mayo.edu) (I.I. Aleksandrovich).